PROMMIS Study Data Highlights SKY92's Efficacy in Identifying High-Risk Multiple Myeloma Patients

SkylineDx, a company renowned for its innovative diagnostics in oncology, inflammatory, and infectious diseases, has revealed pivotal data on the SKY92 Classifier's prognostic value in multiple myeloma. This information will be showcased at the American Society of Hematology (ASH) conference. The findings come from the PROMMIS real-world study, which was conducted across nine academic cancer centers in the United States. Dr. Noa Biran, an Associate Professor at Hackensack Meridian School of Medicine, will present the study, underscoring SKY92's significant impact on risk stratification for multiple myeloma patients.

Multiple myeloma is a type of blood cancer known for its complex molecular characteristics. Even with advancements in treatment, patients identified as high-risk often face poor survival rates. Traditionally, risk assessment in multiple myeloma has focused on cytogenetic aberrations. However, the PROMMIS study highlights that the SKY92 gene expression profiling (GEP) classifier provides essential biological insights and serves as an independent prognostic tool.

The study involved 251 newly diagnosed multiple myeloma patients, who were followed up over nearly four years. The findings indicated that individual chromosomal abnormalities and their combinations generally had limited prognostic value. An exception was the 1q21 abnormality, which had prognostic significance for progression-free survival (PFS) only in patients aged 65 and older. In contrast, SKY92 emerged as a more robust predictor of poor outcomes. Patients with the high-risk SKY92 biomarker exhibited significantly worse progression-free survival rates, independent of other genetic abnormalities.

Furthermore, the research demonstrated that combining SKY92 results with specific genetic markers, such as gain(1q21), could provide more comprehensive insights. For instance, patients classified as high-risk by both tests experienced some of the worst outcomes, emphasizing the complementary nature of using SKY92 in conjunction with other genetic markers.

Dr. Jvalini Dwarkasing, Chief Scientific Officer at SkylineDx, highlighted the importance of these findings: "This research underscores how the SKY92 test can significantly enhance the care of multiple myeloma patients. By offering a more precise and reliable method to identify high-risk disease, we equip doctors with powerful tools to tailor treatments and improve patient outcomes. This study reinforces our dedication to advancing personalized medicine."

This research represents a crucial advancement in understanding and treating multiple myeloma. The SKY92 test not only provides a more accurate means of identifying high-risk disease but also helps refine the application of existing genetic information. By incorporating this advanced technology into standard care practices, clinicians can better support patients facing this challenging disease.

SkylineDx extends its gratitude to the patients, physicians, and research teams involved in the PROMMIS study, recognizing that their commitment made this work possible.

The MMprofiler with SKY92 biomarker significantly enhances the biological understanding of multiple myeloma, a disease known for its variability among patients. This molecular diagnostic test measures the activity of 92 genes in malignant myeloma plasma cells to determine the aggressiveness of the disease. For patients with high-risk disease, traditional treatments are often less effective, necessitating more intensive therapy. The MMprofiler with SKY92 is CE-IVD registered in Europe and available as a laboratory-developed test (LDT) from SkylineDx’s CAP/CLIA lab in San Diego, California.

SkylineDx, headquartered in Rotterdam, the Netherlands, with operations in San Diego, California, is dedicated to the research and development of molecular diagnostics in oncology, inflammatory, and infectious diseases. The company bridges the gap between academically discovered gene expression signatures and commercially available diagnostic products with high clinical utility, enabling healthcare professionals to accurately diagnose disease types, predict patient responses to treatments, and tailor personalized treatment plans.